300363.SHE Porton Fine Chemicals Ltd
- Market cap
- CNY 12.1B
- P/E
- -
- P/B
- 2.53x
- ROE
- -3.0%
- Dividend yield
- 0.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300363.SHE undervalued?
Graham numberThe Graham number of Porton Fine Chemicals Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Porton Fine Chemicals Ltd fundamental analysis
No fundamental analysis for Porton Fine Chemicals Ltd yet.
Porton Fine Chemicals Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Porton Fine Chemicals Ltd
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial in China and internationally. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. It also offers crystallizat…
Full company profilePorton Fine Chemicals Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Porton Fine Chemicals Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.33B | 1.18B | 1.18B | 1.55B | 2.07B | 3.11B | 7.03B | 3.67B | 3.01B | 3.42B | 3.69B |
| Gross Profit | 500M | 429M | 390M | 550M | 835M | 1.26B | 3.64B | 1.44B | 703M | 1.02B | 1.24B |
| Operating Income | 196M | 115M | 154M | 195M | 352M | 566M | 2.27B | 269M | -342M | 211M | 367M |
| EBITDA | 312M | 286M | 237M | 295M | 498M | 720M | 2.45B | 581M | 95.9M | 559M | -97.4M |
| Net Income | 171M | 107M | 124M | 186M | 324M | 524M | 2.01B | 267M | -288M | 96.3M | -150M |
| EPS | 0.40 | 0.25 | 0.26 | 0.35 | 0.61 | 0.98 | 3.69 | 0.49 | -0.53 | 0.18 | -0.28 |
| Balance Sheet | |||||||||||
| Total Assets | 2.87B | 2.85B | 4.37B | 3.96B | 4.50B | 6.56B | 10.1B | 9.38B | 8.82B | 8.55B | 8.02B |
| Total Liabilities | 1.50B | 1.40B | 1.49B | 891M | 1.10B | 2.38B | 3.67B | 3.28B | 3.40B | 3.05B | 2.87B |
| Shareholders' Equity | 1.28B | 1.38B | 2.88B | 3.07B | 3.39B | 3.98B | 6.00B | 5.80B | 5.20B | 5.35B | 5.05B |
| Cash & Short-term Investments | 459M | 308M | 2.06B | 1.17B | 1.27B | 1.22B | 2.85B | 1.97B | 1.47B | 1.13B | 978M |
| Total Debt | 1.04B | 958M | 1.15B | 347M | 413M | 741M | 924M | 1.71B | 1.57B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 285M | 289M | 194M | 351M | 504M | 480M | 2.56B | 629M | 406M | 757M | - |
| Capital Expenditure | 189M | 159M | 168M | 175M | 394M | 777M | 1.17B | 1.13B | 491M | 293M | 149M |
| Free Cash Flow | 96.8M | 131M | 25.5M | 176M | 110M | -297M | 1.39B | -501M | -85.1M | 464M | 465M |
| Ratios | |||||||||||
| ROE | 13.3% | 7.8% | 4.3% | 6.1% | 9.6% | 13.2% | 33.4% | 4.6% | -5.5% | 1.8% | -3.0% |
| ROA | 6.0% | 3.8% | 2.8% | 4.7% | 7.2% | 8.0% | 19.8% | 2.8% | -3.3% | 1.1% | -1.9% |
| Net Profit Margin | 12.9% | 9.1% | 10.5% | 12.0% | 15.7% | 16.9% | 28.5% | 7.3% | -9.6% | 2.8% | -4.1% |
| Debt to Equity | 0.81x | 0.70x | 0.40x | 0.11x | 0.12x | 0.19x | 0.15x | 0.30x | 0.30x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Porton Fine Chemicals Ltd dividends
- Dividend yield
- 0.25%
- Forward dividend
- 0.09 CNY
- Payout ratio
- 31.2%
- Ex-dividend date
- May 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 30.1M | 0.06 | 31.2% |
| 2024 | CNY 301M | 0.56 | - |
| 2023 | CNY 627M | 1.15 | 234.8% |
| 2022 | CNY 105M | 0.19 | 5.2% |
| 2021 | CNY 65.4M | 0.12 | 12.5% |
| 2020 | CNY 55.8M | 0.10 | 17.2% |
| 2019 | CNY 25.1M | 0.05 | 13.5% |
| 2018 | CNY 74.4M | 0.16 | 59.7% |
| 2017 | CNY 76.0M | 0.18 | 70.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on Sep 29, 2015.
Who owns Porton Fine Chemicals Ltd
- Insiders 44.72%
- Institutions 4.62%
- Public & others 50.66%
- Shares outstanding 537M
- Free float 296M
Porton Fine Chemicals Ltd company profile
- Company name
- Porton Fine Chemicals Ltd
- Ticker
- 300363.SHE
- ISIN
- CNE100001S57
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,359
- Fiscal year end
- December
- Address
- No.7, Yuntu Road, Chongqing, China, 400714
- Phone
- 86 23 6593 6900
- Website
- portonpharma.com
About Porton Fine Chemicals Ltd
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial in China and internationally. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. It also offers crystallization, bio catalysis, metal catalysis, flow chemistry, prep-chromatography, and milling. Porton Pharma Solutions Ltd. was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. The company was incorporated in 2005 and is headquartered in Chongqing, China.
Porton Fine Chemicals Ltd management
7- Mr. Nianfeng JuChairman & GM · born 1972
- Mr. Hui ChenDeputy GM & CFO · born 1979
- Mr. Yinchun BaiSenior Deputy GM, COO & Employee Representative Director · born 1973
- Ms. Wei PiDeputy GM & Secretary of the Board of Directors · born 1987
- Mr. Po ZhuDeputy General Manager · born 1970
- Mr. Qi ChenDeputy General Manager · born 1977
- Ya Qian RuanAccounting Supervisor